Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (8075)	12/16/1998 8:44:00 AM
From: opalapril	Respond to of 17367

Isn't the DSMB meeting this month? Anyone expecting a company announcement before the board dons Bermuda shorts & flowered shirts at the end of the month?

To: Robert K. who wrote (8075)	12/16/1998 8:57:00 AM
From: Robert S.	Respond to of 17367

Robert K, Briefly: anti-endotoxin strategies, as we have seen, may not be a viable therapeutic option for sepsis. If BPI does work, it will indeed be used, but not in an indiscriminate manner. There are many antibiotic potentiators available. For example: Clin Infect Dis 1998 May;26(5):1169-76 In vitro antibiotic synergy against Flavobacterium meningosepticum: implications for therapeutic options. Di Pentima MC, Mason EO Jr, Kaplan SL Department of Pediatrics, Texas Children's Hospital, Houston 77030, USA. Flavobacterium meningosepticum is an unusual, highly resistant, gram-negative bacillus that is associated with neonatal meningitis and nursery outbreaks of meningitis. The optimal therapy for this infection is not known. We successfully treated three neonates with intravenous vancomycin and rifampin. We determined the in vitro activity of meropenem, ciprofloxacin, vancomycin, linezolid (PNU-100766), and rifampin, alone and in combination, against four isolates of F. meningosepticum from neonates with sepsis and meningitis. MICs were determined by tube dilution, and fractional inhibitory concentrations were calculated with use of the checkerboard microtiter dilution technique. Synergy was observed between rifampin and vancomycin against three isolates, while combinations of vancomycin, ciprofloxacin, and linezolid showed an additive effect against all isolates. These results support the clinical evidence that the combination of vancomycin and rifampin is an appropriate regimen for neonatal meningitis due to F. meningosepticum. The combination of meropenem and vancomycin was antagonistic. The clinical efficacy of combinations including ciprofloxacin, newer quinolones, or linezolid for treating F. meningosepticum meningitis deserves further study. Publication Types: Review Review of reported cases PMID: 9597247, UI: 98259535

To: Robert K. who wrote (8075)	12/16/1998 12:03:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

LBP patent, competition from India. Text mentions XOMA. 164.195.100.11

To: Robert K. who wrote (8075)	12/17/1998 11:06:00 AM
From: aknahow	Respond to of 17367

Bob, thanks for this great site of accurate scientific information! Find it to be one of the best. Have deleted Medline, Nature, Science and hundreds of other bookmarks now that I have found this new and better source. However, I thought this disease was spread in the air. Does the. "fact" that it's spread by water have anything to do with Ellen's interest in water? Again many thanks, and I now understand better why you can't bother with TSC. nationalenquirer.com:80/stories/story-70839.html